Adnan Javaid, MD
Pulmonary Disease · Kernersville, NCNPI 1881879310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,600 of the $67,267 with a category attached, or 73.7%. GSK accounts for 76.6% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2020 at $48,876 and has fallen 97.7% since, to $1,129 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 815 payments — averaging $82.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$52K
- AstraZeneca$4K
- Viiv Healthcare Company$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$1K
- Mylan Specialty L.p.$689
- plus $7K from 41 others
Across 11 payments — averaging $11,764 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mylan Specialty L.p.$91K
- AstraZeneca$38K
What the payments were for
- Consulting fees$1,5172%
- Speaking & faculty fees$49,60074%
- Travel & lodging$4081%
- Food & beverage$15,47823%
- Education$2640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$23,361
- ANORO ELLIPTA$21,712
- ANORO$3,844
- BREZTRI AEROSPHERE$1,517
- FASENRA$359
- BEVESPI AEROSPHERE$125
- SYMBICORT$125
- FARXIGA$125
- ZEPBOUND$125
- HYQVIA$120
- SUNOSI$107
- NUCALA$100
How this compares
$67,267 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 353 | $315,192 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 205 | $156,345 |
| Breo ElliptaFluticasone/Vilanterol | 160 | $69,810 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $65,820 |
| SymbicortBudesonide/Formoterol Fumarate | 152 | $55,526 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 81 | $48,973 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $44,092 |
| Spiriva RespimatTiotropium Bromide | 36 | $27,936 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $16,900 |
| Pirfenidone | 22 | $15,384 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 427 | $12,365 |
| Epinephrine | 63 | $9,732 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $8,505 |
| Wixela InhubFluticasone Propion/Salmeterol | 39 | $4,334 |
| Ventolin HfaAlbuterol Sulfate | 60 | $4,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $51,517 | $429,094582 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $4,088 | $215,978368 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $1,256 | $76,909117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $588 | $65,82013 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $9,73263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Kernersville
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.